Pipeline

Complementary platforms that act alone or in combination with other treatments to address conditions of severe unmet medical need.

Nibrozetone (RRx-001) & AdAPT Program

Supportive Care (RRx-001)
Study Indication Preclinical Phase 1 Phase 2 Phase 3
KEVLARx Severe Oral Mucositis
Cancer (AdAPT-001)
Study Indication Preclinical Phase 1 Phase 2 Phase 3
BETA PRIME Sarcoma (soft-tissue)
Neurodegenerative Diseases (RRx-001)
Indication Grants Preclinical Phase 1
Parkinson’s Michael J Fox Foundation Therapeutic Pipeline Program
ALS/MND FightMND Drug Development Program Grant
Neuroprotection Awarded - to be announced
Toxic Exposures Awarded - to be announced
Endometriosis (RRx-001)
Study Indication Preclinical Phase 1 Phase 2 Phase 3
In Start-up Endometriosis
Active programs

Partnership Opportunities: We welcome regional and global partnerships with like-minded companies, institutions, and investors that support our first-in-class therapies and treatment programs in oncology, radioprotection, and neurodegenerative and gynecological diseases.